Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429000 | 0.80 | KDR (0.45) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL3121622 | 0.76 | HTT (0.63) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL3891272 | 0.76 | KDR (0.60) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2577752 | 0.76 | P2RX1 (0.60) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL3110902 | 0.76 | GRM4 (0.61) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL3456598 | 0.74 | HTT (0.62) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL29377800 | 0.73 | GRM4 (0.55) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL17643720 | 0.73 | GRM4 (0.55) | MEN1KMT2AHTTALDH1A1MAPT | |
| SCHEMBL16097545 | 0.72 | KCNQ3 (0.57) | — | |
| SCHEMBL444897 | 0.72 | ALDH1A1 (0.51) | MEN1KMT2AHTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | MEN1 1464/4885KMT2A 1313/4885HTT 1959/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | MEN1 1584/4885KMT2A 1046/4885HTT 1813/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | MEN1 2237/4885KMT2A 1457/4885HTT 1392/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | MEN1 664/4885KMT2A 1259/4885HTT 2723/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | MEN1 2237/4885KMT2A 1457/4885HTT 1392/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | MEN1 664/4885KMT2A 1259/4885HTT 2723/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | MEN1 1584/4885KMT2A 1046/4885HTT 1813/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | MEN1 1555/4885KMT2A 1075/4885HTT 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.